Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Larimar Therapeutics in a research note issued to investors on Monday, December 16th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.77) per share for the year, down from their previous estimate of ($1.57). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Larimar Therapeutics' FY2026 earnings at ($1.99) EPS.
A number of other analysts also recently commented on the company. Robert W. Baird started coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an "outperform" rating and a $16.00 price target for the company. Baird R W upgraded shares of Larimar Therapeutics to a "strong-buy" rating in a report on Wednesday, September 4th. Oppenheimer began coverage on shares of Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an "outperform" rating and a $26.00 target price on the stock. Wedbush began coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They set an "outperform" rating and a $22.00 price target for the company. Finally, William Blair reissued an "outperform" rating on shares of Larimar Therapeutics in a report on Tuesday, November 19th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $20.43.
Get Our Latest Stock Report on LRMR
Shares of LRMR traded down $0.13 during trading hours on Thursday, reaching $4.03. 240,308 shares of the stock traded hands, compared to its average volume of 621,062. Larimar Therapeutics has a 52 week low of $3.01 and a 52 week high of $13.68. The stock has a fifty day simple moving average of $7.03 and a 200 day simple moving average of $7.68. The company has a market cap of $257.14 million, a price-to-earnings ratio of -3.50 and a beta of 0.86.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.13. During the same quarter last year, the company posted ($0.21) EPS.
Several institutional investors and hedge funds have recently modified their holdings of LRMR. Quarry LP grew its holdings in shares of Larimar Therapeutics by 966.7% during the 2nd quarter. Quarry LP now owns 8,000 shares of the company's stock valued at $58,000 after purchasing an additional 7,250 shares during the last quarter. Quest Partners LLC grew its stake in shares of Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company's stock valued at $60,000 after buying an additional 5,796 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Larimar Therapeutics during the third quarter valued at about $71,000. Intech Investment Management LLC purchased a new position in shares of Larimar Therapeutics in the third quarter worth about $85,000. Finally, Thoroughbred Financial Services LLC bought a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at about $94,000. Hedge funds and other institutional investors own 91.92% of the company's stock.
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.